Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01021215 · ClinicalTrials.gov registry record · Phase 1
Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT01021215: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01021215 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01021215, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how zileuton alone or the combination of zileuton and celecoxib may affect certain chemicals in the body that may be linked with a risk for smoking-related lung disease. These effects will be measured by a urine test
Interventions
- OTHER laboratory biomarker analysis
- DRUG Celecoxib
- DRUG Zileuton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01021215
The ClinicalTrials.gov registry entry for NCT01021215 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01021215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01021215 about?
NCT01021215 is a clinical study titled "Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers". The goal of this clinical research study is to learn how zileuton alone or the combination of zileuton and celecoxib may affect certain chemicals in the body that may be linked with a risk for smoking-related lung disease. These effects will be measured by a urine test
What is the current status of trial NCT01021215?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2010-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01021215?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Celecoxib (DRUG), Zileuton (DRUG).
Who is sponsoring clinical trial NCT01021215?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.